Relay Therapeutics, Inc. (RLAY) - Form 8-K Summary
Business Context and Reporting Period
Relay Therapeutics, Inc., a Delaware corporation headquartered in Cambridge, Massachusetts, filed this Current Report on Form 8-K on February 26, 2026. The filing announces the company's financial results for the quarter and full year ended December 31, 2025.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) for detailed data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics for the reported period.
Material Changes
Specific material changes versus the prior comparable period are not detailed in the text of this Form 8-K. The document indicates that such operational and financial details are contained within the furnished press release.
Guidance, Outlook, and Risks
The filing text does not contain specific guidance, management commentary, risk factors, or contingencies. It explicitly states that the information furnished is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for Q4 and FY 2025.
- Verify the company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the accompanying materials.
- Confirm if there were any changes in capital structure or debt obligations during the period.